Histological expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanoma

Pathology

Volumn 36, Issue 6, 2004, Pages 561-565

  Bron, Luc P ^a   Scolyer, Richard A ^a   Thompson, John F ^a,b   Hersey, Peter ^a,c,d  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b University of Sydney   (Australia)

^c NEWCASTLE MATER HOSPITAL   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Apoptosis; Cutaneous melanoma; Pathology; TRAIL; Tumor necrosis factor related apoptosis inducing ligand; Tumour necrosis factor related apoptosis inducing ligand

Indexed keywords

TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CHI SQUARE TEST; FEMALE; FISHER EXACT TEST; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPHOCYTIC INFILTRATION; MALE; MELANOMA; MITOSIS RATE; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; THICKNESS; TUMOR CELL CULTURE; ULCER;

EID: 11844277663     PISSN: 00313025     EISSN: None     Source Type: Journal    
DOI: 10.1080/00313020400011268     Document Type: Article

References (33)

1. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanism. Curr Opin Immunol 1998; 10: 559-63.
2. Pitti RM, Masters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumour necrosis factor cytokine family. J Biol Chem 1996; 271: 12687-90.
3. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-82.
4. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998; 161: 2833-40.
5. Phillips TA, Ni J, Pan G, et al. TRAIL (Apo2L) and TRAIL receptors in human placentas: implication for immune privilege. J Immunol 1999; 162: 6053-9.
6. Rieger J, Naumann U, Glaser T, Ashkeuazi A, Weller M. APO2 ligand a novel lethal weapon against malignanl glioma? FEBS Lett 1998; 427: 124-8.
7. Thomas WD, Hersey P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol 1998; 161: 2195-200.
8. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999; 59: 2747-53.
9. Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersey P. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 2000; 482: 193-9.
10. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2: 420-30.
11. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumour activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-62.
12. Gliniak B, Le T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 1999; 59: 6153-8.
13. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumour necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-63.
14. Gura T. How TRAIL kills cancer cells but not normal cells. Cancer Res 1997; 277: 768.
15. Nguyen T, Thomas W, Zhang XD, Gray C, Hersey P. Immunologically-mediated tumour cell apoptosis: the role of TRAIL in T-cell and cytokine-mediated responses to melanoma. Forum 2000; 10: 243-52.
16. Kayagaki N, Yamaguchi N, Nakayama M, Kawasaki A, Akiba H, Okumura KYH. Involvement of TNF-related apoptosis-inducing ligand in human T cell-mediated cytotoxicity. J Immunol 1999; 162: 2639-47.
17. Takeda K, Hayakawa Y, Smyth MJ. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001; 7: 94-100.
18. Fanger NA, Maliszewski CR, Schooley K, Griffith TS. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 1999; 190: 1155-64.
19. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA. Monocyte-mediated tumoricidal activity via the tumor necrosis factor related cytokine, TRAIL. J Exp Med 1999; 189: 1343-54.
20. Kemp TJ, Elzey BD, Griffith TS. Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation. J Immunol 2003; 171: 212-8.
21. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999; 189: 1451-60.
22. Gratas C, Tohma Y, Meir EGV, et al. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol 1997; 7: 863-9.
23. Niehans GA, Brunner T, Frizelle SP, et al. Human lung carcinoma express Fas Ligand. Cancer Res 1997; 57: 1007-12.
24. Shiraki K, Tsuji N, Shioda T, Isselbacher KJ, Takahashi H. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 1997; 94: 6420-5.
25. Hahne M, Rimoldi D, Schröter P, et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274: 363-4.
26. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T Cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-82.
27. Giovarelli M, Musiani P, Garotta G, et al. A 'stealth effect': Adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions. J Immunol 1999; 163: 4886-93.
28. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is more powerful prognostic indicator than ulceration in patients with primary cutaneous melanomas: an analysis of 3661 patients from a single center. Cancer 2003; 97: 1488-98.
29. Beatu TM, Kwon H, Sharma S, Garndvaux N, Hiscott J. Disruption of NF-kappaB signaling reveals a novel role for NF-kappaB in the regulation of TNF-related apoptosis-inducing ligand expression. J Immunol 2001; 167: 3164-73.
30. Dhawan P, Singh AB, Ellis DL, Richmond A. Constitutive activation of Akt/protein kinase B in melanoma leads to regulation of nuclear factor kappaB and tumor progression. Cancer Res 2002; 62: 7335-42.
31. Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, Jeremias I. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 2003; 22: 3842-52.
32. Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor apoptosis. J Immunol 2000; 165: 2886-94.
33. Strebel A, Bachman F, Wernli M, Erb P. Tumor necrosis factor-related apoptosis-inducing ligand supports growth of mouse mastocytoma tumors by killing tumor-infiltrating macrophages. Int J Cancer 2002; 100: 627-34.